Omalizumab is a monoclonal anti-IgE antibody that was approved by the FDA in 2003 for the treatment of moderate-persistent uncontrolled allergic asthma with inhaled corticosteroids, being the first biologic used for type 2 inflammatory diseases.13, 15, 16, 17 Studies have shown improvements in asthma control, a reduction in the number of exacerbations, and a decreased need for oral corticosteroids and rescue medications.15 The gene discussed is IGHE; the disease is asthma.